Kornimate/medical-research-clean huggingface dataset:
presence and comparison of sarcopenia in early rheumatoid arthritis and rheumatoid arthritis

Conditions: Sarcopenia

Summary: introduction: in this study, the presence of sarcopenia in cases with early rheumatoid arthritis and established rheumatoid arthritis will be compared. materials and method: according to the power analysis, 24 patients with early rheumatoid arthritis and 24 patients with established rheumatoid arthritis who meet the 2010 american college of rheumatology (acr) / european alliance of associations for rheumatology (eular) rheumatoid arthritis (ra) classification criteria will be included in the study.

according to the power analysis, 24 patients with early rheumatoid arthritis and 24 patients with established rheumatoid arthritis who met the 2010 acr / eular ra classification criteria will be included in the study. the presence of sarcopenia will be evaluated according to the european working group on sarcopenia in older people (ewgsop-2) criteria by performing hand grip strength, muscle mass measurement with bioelectrical impedance analysis (bia), and 4-meter general walking speed tests. demographic data of the patients and anti-nuclear antibody (ana), rheumatoid factor (rf) and anti-cyclic citrullinated peptide (anti-ccp) levels, simplified disease activity index (sdai), clinical disease activity index (cdai), disease activity score ( das)28, functional status (health assessment questionnaire (haq)), quality of life (ra quality of life scale (raqol)), anxiety and depression (hospital anxiety and depression scale (hads)) results will be evaluated.

Eligibility criteria:
inclusion criteria: inclusion criteria for the early ra group: * to be diagnosed with ra according to the 2010 acr (american society for the study of rheumatism) / eular (european association for the study of rheumatism) ra classification criteria * being 18 years or older * being followed up with a diagnosis of ra for less than 1 year (early ra) inclusion criteria for the ra group: * to be diagnosed with ra according to the 2010 acr (american society for the study of rheumatism) / eular (european association for the study of rheumatism) ra classification criteria * being 18 years or older exclusion criteria: * presence of other rheumatic disease * presence of malnutrition * recent surgical history, * stroke history, * pregnancy, * presence of prosthesis or metal implant, * presence of a pacemaker, * patients over 140 kg

Keywords: early rheumatoid arthritis sarcopenia rheumatoid arthritis appendicular skeletal muscle mass index
a model for genetic susceptibility: melanoma

Conditions: Melanoma; Skin Cancer

Summary: the goal of this study is to find out if some people are more likely to get melanoma, a form of skin cancer, than others are. to do this we will compare people who have had more than one melanoma to people who have had only one melanoma and to people who are similar but who have not developed melanoma. people respond to the environment in different ways. some may be born with genes that make them more likely to get this type of skin cancer. each person has many ways to repair normal damage to their genes. specific genes may affect the repair of sun damage. other genes affect the way the skin itself reacts to the sun. we want to find out which genes have normal changes in them and lead to different responses to exposures, such as the sun. we also want to find out if sun habits are related to the way these genes work.

the purpose of this study is to better understand genetic susceptibility to melanoma and the interactions of specific polymorphisms with each other and with environmental factors. to accomplish this, buccal swabs or blood specimens from patients with melanoma (either single primary or multiple primary) have been collected. specimens will be prepared in the epidemiology laboratory at mskcc. they will be analyzed at mskcc for ink4a (and functional assays for dna repair capacity when blood is available) and the melanocortin gene (mc1r), at the university of north carolina for polymorphisms in dna repair genes and immune function genes, at the university of pennsylvania for polymorphisms in the melanocortin receptor gene (mc1r) and immune function genes, and at the university of california (irvine) for polymorphisms in metabolizing genes (p450's and gst's). samples will be banked at mskcc and the university of new mexico. in order to perform this study, subjects from population-based registries in the united states (new jersey, north carolina, michigan, san diego/imperial counties), canada (cancer care ontario, british columbia), italy (turin), australia (new south wales, tasmania), were interviewed, asked to provide blood or buccal swab samples and asked to provide permission to obtain and review slides of their primary melanoma. this study is now closed to accrual.

Eligibility criteria:
inclusion criteria: - the subject must have a histologically confirmed invasive first primary melanoma newly diagnosed between january 1, 2000 and december 31, 2000. or the subject must have a histologically confirmed invasive or in situ second primary melanoma newly diagnosed between january 1, 1998 and december 31, 2003. one of the earlier primaries must be invasive melanoma or the subject must be a randomly ascertained control from the general. - the patient must be a resident of a one of the specific geographic areas participating in this study. exclusion criteria: * subjects who do not speak english or italian * subject is unable to sign informed consent * subject is unable to participate in telephone interview

Keywords: melanoma skin cancer genetic susceptibility polymorphisms
brimonidine purite 0.15% versus dorzolamide 2% used as adjunctive therapy to latanoprost

Conditions: Glaucoma

Summary: evaluate the relative efficacy and tolerability of alphagan p compared to trusopt as adjunctive therapy


Eligibility criteria:
inclusion criteria: * · male or female \> 18 years of age * diagnosis of open-angle glaucoma or ocular hypertension * iop \> 16 mm hg in each eye at the latanoprost -treated baseline evaluation * presently on latanoprost monotherapy for at least 6 weeks * ability to provide informed consent and likely to complete all study visits exclusion criteria: * · known contraindication or allergy to brimonidine or any of its components * subjects must be naive to brimonidine 0.2% or brimonidine purite 0.15% and dorzolamide 2% * uncontrolled systemic disease * active ocular disease other than glaucoma or ocular hypertension (e.g. uveitis, ocular infections, or severe dry eye). patients with chronic mild blepharitis, cataract, age-related macular degeneration, or background diabetic retinopathy may be enrolled at the discretion of the investigator. * required use of ocular medications other than the study medications during the study (intermittent use of artificial tear product is allowed). * corneal abnormalities * history of intraocular surgery within the last 3 months * female patients of childbearing potential who are pregnant, lactating, planning a pregnancy, or not using a reliable form of birth control * visual field loss, which in the opinion of the investigator, is functionally significant, or evidence of progressive visual field loss within the last year.
ankle-foot orthoses for peripheral artery disease

Conditions: Peripheral Artery Disease

Summary: the primary aim of this study is to investigate the effect of an ankle foot orthoses (afo) on the primary outcome of peak walking time (pwt) in patients with peripheral artery disease (pad).

the investigators will test the hypothesis that pad patients using an afo during a graded exercise test will demonstrate a greater pwt compared to pwt assessed without the use of an afo. secondary hypotheses include evaluation of the effect of an afo on: 1) calf muscle function, 2) claudication onset time, 3) functional ability, 4) peak oxygen consumption, and 5) patient-reported outcomes. we will also examine the effects of the afo on outcomes following 12 weeks of community walking.

Eligibility criteria:
inclusion criteria: * men and women diagnosed with atherosclerotic peripheral arterial disease (pad). * patients who experience calf claudication * ≥40 years of age * an abnormal ankle-brachial index (abi) of ≤.90. * for patients with an abi \>.90 and \<1.00, a post-exercise abi drop of 15% or more compared to the resting abi exclusion criteria: * lower extremity amputation(s) which interfere(s) with walking. * critical limb ischemia (i.e., ischemic rest pain, ulcers/gangrene on the lower extremities). * non-atherosclerotic pad (e.g., popliteal entrapment syndrome, takayasu's arteritis) * major surgical procedures that are contraindicated to an exercise program (e.g., recent organ transplant) or coronary artery bypass graft within 6 months prior to screening. * primarily limitations to exercise due to chronic obstructive pulmonary disease, angina or heart failure. * myocardial infarction within 3 months prior to screening. * acute coronary syndrome symptoms diagnosed at time of screening. * significant ischemic changes (documented on the 12-lead electrocardiogram) with horizontal or down-sloping st-segment depression ≥ 0.5mm at rest and \>1 mm with exercise in 3 beats for 2 contiguous leads, relative to the pr-segment (or st-segment elevation ≥1mm). * transient ischemic attack or stroke 3 months prior to screening. * new left bundle branch block or sustained ventricular tachycardia \>30 seconds during screening. * uncontrolled hypertension defined as ≥180 systolic or ≥100 diastolic resting blood pressure during screening. * women who are pregnant (women of childbearing potential, a pregnancy test will be performed at screening. * individuals currently incarcerated. * evidence of acute impairment from alcohol or other illicit drugs. * lack of diabetes control (glycated hemoglobin \>12%) * patients who are anemic (hgb \<11 g/dl for women and \<10 g/dl for men). * any other clinically significant diseases (e.g., pulmonary, renal, psychiatric, immunological) that are not stabilized or may otherwise confound the results of the study.

Keywords: claudication ankle foot orthoses community walking exercise
clinical and microbiologic outcomes of adjunctive antimicrobial photodynamic therapy in the non-surgical and surgical treatment of teeth with periodontal disease

Conditions: Periodontal Diseases

Summary: the purpose of this study is to compare clinical outcomes after mechanical debridement of at sites exhibiting plaque induced inflammation with or without adjunctive antimicrobial photodynamic therapy (apdt) and to assess the the microbiologic profile before and after treatment with or without apdt


Eligibility criteria:
inclusion criteria: * one pocket on each side of the mouth (split design) * single rooted tooth * pocket depths measured greater than 4mm with bleeding on probing * horizontal bone loss * no furcation involvement exclusion criteria: * current heavy smokers (\>10 cigarettes/day) * have uncontrolled diabetes (hba1c ≥ 6.5%) * other uncontrolled systemic diseases that may comprise healing, such as vitamin c deficiency, any neutrophil deficiencies, immunodeficiency syndromes, or leukemia * taking antibiotics within 3 months before the procedure * vertical bone defects that requires surgical regenerative treatment. * pregnancy

Keywords: plaque laser therapy
twice weekly tp-hdfl for recurrent or metastatic esophageal cancer

Conditions: Esophageal Cancer

Summary: the primary objective of this study is to find out the response rate of twice weekly paclitaxel and cisplatin and weekly hdfl in recurrent or metastatic esophageal carcinoma patients who need palliative chemotherapy.

the primary objective of this study is to find out the response rate of twice weekly paclitaxel and cisplatin and weekly hdfl in recurrent or metastatic esophageal carcinoma patients who need palliative chemotherapy. the secondary objectives include overall survival, progression-free survival, and toxicity.

Eligibility criteria:
inclusion criteria: * pathologically proven esophageal squamous cell or adenocarcinoma recurrence or metastasis measurable disease (\> 1 x 1 cm) by cxr, ct scan or mri,age \> 18, kps \> 60% , cre \ 4,000/mm3, anc \> 2,000/ mm3, plt \> 100,000/mm3 exclusion criteria: * prior chemo (except as radiosensitizers)recurrent, treated esophageal lesion only (except \> 2 months)

Keywords: combination,chemotherapy,esophageal cancer
preventing invasive cervical cancer: the importance of expectant management in young women with high-grade pre-cancerous lesions

Conditions: High-Grade Squamous Intraepithelial Lesions

Summary: lesions classified as "high grade squamous intra-epithelial lesions" (hsil) are pre-cervical lesions of the cervix, induced by infection with the human papilloma virus (hpv). the detection and proper management of these lesions greatly reduces the incidence of invasive cervical cancer. pap smear remains the most effective tool for early detection of low and high-grade cervical lesions. in belgium, screening for cervical cancer is recommended every 3 years for women between 25 and 65 years old. hpv is a virus who possesses certain oncogenic genes who have the ability to inactivate tumor suppressor genes in the host cell. this promotes a tumorigenesis process within the tissues affected by the virus. the majority of human papillomavirus infections are transient and spontaneously cleared by host defense mechanisms, especially in the first two years after exposure. however, 10-20% of infections persist latently and may eventually lead to progression to invasive cervical cancer. even high-grade lesions kan naturally be cleared, even more so if the patient is young and immuno-competent. therefore, the management of hsil lesions in young women has been modified and consists of adopting mainly a conservative attitude, with controls every 6 months for 2 years. this management makes it possible to avoid unnecessary conizations of the cervix which, in young nulliparous patients, are not devoid of heavy obstetric consequences during subsequent pregnancies (premature birth, perinatal mortality). cervical conization will only be considered for lesions that progress during follow-up or that persist beyond 2 years. however, this type of follow-up requires that patients be compliant. our study has two main objectives: * to determine the compliance of chu brugmann hospital patients who have been proposed a conservative strategy for the management of hsil lesions. * to identify the predictive factors for the persistence and / or progression of high-grade pre-cancerous dysplastic lesions.


Eligibility criteria:
inclusion criteria: * patients followed within the chu brugmann hospital (no private practices). * hsil lesions confirmed by anatomopathologic analysis on cervical biopsies or cone specimen without evidence of invasive lesions exclusion criteria: * invasive lesions
safety and pharmacokinetics of sancuso and iv granisetron in patients aged 13 to 17 years

Conditions: Chemotherapy Induced Nausea and Vomiting

Summary: the purpose of this study is to determine the dosing strategy for adolescents aged 13 to 17 years.


Eligibility criteria:
inclusion criteria: 1. 13 to 17 years of age inclusive at screening. 2. written patient or parental (or appropriate legal representative) irb approved informed consent as appropriate. 3. written patient assent (as appropriate). 4. confirmed malignancy. 5. scheduled to receive 2 or more cycles\* of emetogenic chemotherapy requiring 5-ht3 antagonist treatment. 6. scheduled to receive one or more consecutive days of 5-ht3 antagonist treatment, per cycle, as cinv prophylaxis. * the cycles of chemotherapy must be consecutive (i.e. one followed by the other) but do not have to be the first and second cycle of a line of treatment. exclusion criteria: 1. hypersensitivities, allergies or contraindications to study medications; intolerance of medical tape or sticking plaster. 2. clinical or laboratory signs and symptoms of significant cerebral, cardiovascular, respiratory, renal, hepatobiliary, pancreatic or infectious disease, which in the investigator's judgment may interfere with the study assessment or completion of the study. 3. patients with a known history or predisposition to cardiac conduction interval abnormalities, including qt syndrome, or known family history of long qt syndrome or taking medications that are known to prolong the qt interval. 4. patients scheduled to have routine surgery during the study duration. 5. patients with a life expectancy of \< 6 months. 6. scarring or significant skin disease on both upper arms. 7. female patients who are pregnant or breast-feeding. all post menarche female patients must have a pregnancy test at screening. 8. patients who are known or thought to be sexually active must use effective birth control.\*\* 9. administration of other investigational drugs within 30 days preceding the screening visit, except for anticancer treatments. 10. any conditions associated with non-compliance. * effective birth control includes absolute abstinence, or double barrier birth control methods, i.e. condom and one of the following: combined oral contraceptive, diaphragm, depot contraceptive injection.

Keywords: cinv
bevacizumab (avastin) in unresectable/recurrent hemangioblastoma from von-hippel-lindau disease

Conditions: Hemangioblastomas; Von Hippel Lindau Disease

Summary: von hippel-lindau (vhl) disease is an inherited syndrome manifested by a variety of benign and malignant tumors. hemangioblastomas are the most common lesion associated with vhl disease affecting 60-84% of patients with a mean age at diagnosis of 29 years. standard treatment for this disease is by surgery or radiotherapy. no approved systemic therapy yet exists. patients with vhl have an increased growth factor production, specifically vascular endothelial growth factor (vegf), resulting in angiogenesis (growth of blood vessels). studies show that bevacizumab inhibits the growth of vegf protein and will block the vegf-driven angiogenesis and result in stabilization and regression of hemangioblastomas in vhl disease patients. the dose of bevacizumab will be 10 mg/kg every two weeks for up to 6 months.


Eligibility criteria:
inclusion criteria: * one or more cns hemangioblastomas not amendable to surgical resection or recurrent post resection * confirmed diagnosis of von-hippel-lindau disease * no prior treatment with vegf inhibitors * index hemangioblastomas lesion at least 5mm on mri * no major bleeding event from hemangioblastoma within 90 days * kps \> or equal to 60% * age \> or equal to 18 years exclusion criteria: * prior treatment with vegf inhibitors * major bleeding event from hemangioblastoma within 90 days * inability to comply with study and/or follow up procedures * life expectancy of less than 12 weeks * current or recent (within 4 weeks of the first infusion of this study) participation in an experimental drug study other than a genentech sponsored bevacizumab cancer study * active malignancy will be permissible if treating physician deems that concurrent administration of bevacizumab is not contraindicated and that the patient would be able to complete with the other parameters of the protocol

Keywords: hemangioblastoma von hippel lindau vhl lesion egfr
efficacy and safety of azithromycin and artesunate in pregnant women

Conditions: Malaria

Summary: the purpose of this study is to compare the efficacy and safety of three treatment regimens for the prevention of malaria during pregnancy.

malaria infection during pregnancy poses substantial risk to the mother, her fetus, and the neonate. prevention of malaria during pregnancy is vital in decreasing maternal and child mortality in africa. there are data from studies that show that intermittent preventive treatment (ipt) with two doses of sulfadoxine-pyrimethamine (sp) is safe, efficacious, and effective in preventing maternal anemia, placental parasitemia, and lbw. resistance to sp, however, is increasing rapidly in africa and there is an urgent need to find alternative effective, safe and affordable drugs for the treatment and prevention of malaria in pregnancy. the investigators conducted a trial to determine the efficacy and safety of azithromycin and artesunate combined with sulphadoxine-pyrimethamine as treatment against malaria during pregnancy.pregnant women 14 to 26 weeks gestation with p. falciparum parasitemia on peripheral blood film were randomly assigned into 3 treatment groups and received two doses of:(1) sp (3 tablets) only; (2) sp and azithromycin (1gram/day x 2 days)and (3) sp and artesunate 200mg/day for 3 days). the two doses of the study drug were administered approximately 4 weeks apart. all study drugs were taken under observation.blood samples were collected on days 1, 2, 3, 7 and 14 after treatment and at any visit when the women presented with symptoms of malaria. the women were also given an insecticide-treated net (itn) and followed until delivery. adverse effects were assessed at each scheduled visit, any unscheduled visits during the study, and at delivery. peripheral and placental blood films and placental biopsies were prepared at delivery. newborns were weighed, examined, and gestational age was determined.

Eligibility criteria:
inclusion criteria: * peripheral malaria parasitemia * signed informed consent * age 15-49 years * mother has felt the movements of the foetus (quickening) * fetal age of at least 14 but not more than 26 completed gestation weeks * maternal availability for follow-up during the entire period of the study exclusion criteria: * known maternal tuberculosis, diabetes, kidney disease, or liver disease * mental disorder that may affect comprehension of the study or success of follow-up * twin pregnancy * pregnancy complications evident at enrollment visit (moderate to severe oedema, blood hb concentration \ 160 mmhg or diastolic bp \> 100 mmhg) * prior receipt of azithromycin during current pregnancy * receipt of any antimalarial within 28 days before enrollment * known allergy to drugs containing sulfonamides, macrolides or pyrimethamine * history of anaphylaxis * history of any serious allergic reaction to any substance, requiring emergency medical care * history of hepatitis or jaundice * concurrent participation in any other clinical trial

Keywords: malaria pregnancy efficacy azithromycin artesunate